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Summary
Hepatitis C virus (HCV) infection is a leading cause of
chronic hepatitis, liver cirrhosis and hepatocellular car-
cinoma worldwide. Two first-generation protease inhibit-
ors, telaprevir and boceprevir, have recently been approved
for the treatment of chronic hepatitis C genotype 1. Triple
therapy comprising pegylated interferon-α, ribavirin and
telaprevir or boceprevir increases sustained virological re-
sponse rates to ~70% and allows to shorten treatment dur-
ation in ~½ of treatment-naïve patients with chronic hep-
atitis C genotype 1. Sustained virological response rates
in treatment-experienced patients depend on the response
to previous treatment, ranging from >80% in previous re-
lapsers to ~30% in previous null responders. These ad-
vances come at the expense of new adverse effects and
increased cost. In addition, treatment of chronic hepatitis
C will become more complex. In these times of changing
medical practice, the present expert opinion statement by
the Swiss Association for the Study of the Liver shall
provide guidance on the treatment of chronic hepatitis C
with triple therapy comprising telaprevir or boceprevir.
Key words: boceprevir; chronic hepatitis C; HCV;
hepatitis C virus; interferon; protease inhibitor; ribavirin;
telaprevir
Introduction
Hepatitis C virus (HCV) infection is a leading cause of
chronic hepatitis, liver cirrhosis and hepatocellular car-
cinoma (HCC) [1–3]. An estimated 120–200 million indi-
viduals worldwide and about 1% of the general population
in Switzerland are chronically infected with HCV. About
50% of the chronic HCV infections in Switzerland are due
to genotype 1 [4]. While the incidence of acute hepatit-
is C has declined significantly since the introduction of
anti-HCV screening of blood and blood products in 1990,
the number of patients presenting with decompensated cir-
rhosis and HCC is expected to increase further, attaining
a peak around 2020 [1, 5]. More than 50% of the indi-
viduals at risk may currently be unaware of their infection.
Strategies to increase testing and detection rates are cur-
rently being explored (e.g., screening of populations at risk
vs. birth cohort screening) [6, 7].
Fifty to 80% of acutely infected individuals develop per-
sistent infection. Of these, 2–20% will develop liver cir-
rhosis within the first 20 years, and accumulating evidence
suggests that disease progression may increase in a nonlin-
ear fashion thereafter [8]. Once cirrhosis is established, the
rate of HCC development is 1–6% per year. Factors associ-
ated with more frequent and rapid progression to cirrhosis
are, among others, higher age at the time of infection, male
sex, alcohol consumption, coinfections with the human im-
munodeficiency virus (HIV) or hepatitis B virus (HBV),
nonalcoholic fatty liver disease and smoking. Comprehens-
ive management of chronic hepatitis C (CHC) takes these
factors into consideration and aims at improving the ones
that can be modified (alcohol abstinence; weight loss, regu-
lar physical activity and other measures to control the meta-
bolic syndrome; vaccination against HBV [and hepatitis A
virus]; smoking cessation including cannabis) [9].
While non-invasive methods for fibrosis assessment are
actively being pursued [10], liver biopsy remains the ref-
erence for grading and staging of CHC. The Metavir and
Ishak scoring systems are most often applied. Fibrosis
stages are classified from 0 (absence of fibrosis) to 4 (cir-
rhosis) in the Metavir system [11], and from 0 to 6 in the
Ishak system [12].
The decision to treat CHC is based on the analysis of nu-
merous variables and should take into account the specific
situation of each patient. Treatment is clearly recommen-
ded for patients with Metavir fibrosis stage ≥2 who do not
have any contraindications. For other patients, decisions
will have to be made on an individual basis. Additional
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factors that come into consideration are, among others, the
(biological) age and general condition of the patient, the
patient’s personal and professional plans, the duration of
HCV infection, the risk of developing cirrhosis, the likeli-
hood of response to therapy, and comorbidity.
For the last 10 years, standard therapy of CHC consisted
of pegylated interferon-α (PEG-IFN-α) combined with rib-
avirin (RBV) for (16-)24-48(-72) weeks, yielding sustained
virological response (SVR) rates of 40–50% in patients in-
fected with HCV genotype 1 and ~80% in patients infected
with genotypes 2 and 3. Definitions of virological response
patterns are provided in table 1.
Polymorphisms near the IL28B gene have recently been
identified as strong predictors of the outcome of IFN-α-
based antiviral therapy (reviewed in [13, 14]). A number
of laboratories offer IL28B genetic testing, but its role in
clinical practice and decision making, if any, remains to be
defined.
A first generation of directly acting antivirals, the NS3-4A
protease inhibitors telaprevir (TPV; Incivo®) and bocepre-
vir (BOC; Victrelis®), has recently been approved for the
treatment of CHC genotype 1. TPV and BOC have to be
combined with PEG-IFN-α and RBV in order to avoid the
rapid selection of HCV strains resistant to antiviral ther-
apy [15, 16]. Triple therapy comprising TPV or BOC in-
creases SVR rates to ~70% in treatment-naïve patients with
CHC genotype 1 [17–19]. In treatment-experienced pa-
tients, SVR rates depend on the virological response to
previous therapy with PEG-IFN-α and RBV, ranging from
>80% in patients with previous relapse to ~50% in patients
with previous partial response and ~30% in patients with
previous null response [20–22]. Treatment schedules com-
prising TPV or BOC have more side effects than PEG-IFN-
α and RBV, and should be managed carefully.
A significant increase in the number of patients with CHC
to be treated is expected for 2012, with triple therapy re-
gimens that are more complex, as discussed below [23].
These expected developments represent a significant chal-
lenge and will stretch current resources.
The present Swiss Association for the Study of the Liver
(SASL) expert opinion statement is not intended as
guideline but shall provide some guidance on the manage-
ment of CHC genotype 1 and the use of TPV and BOC. It
is based on the results of recently published phase III clin-
ical trials performed in treatment-naïve and treatment-ex-
perienced patients (ADVANCE [17], ILLUMINATE [19]
and REALIZE [20] for TPV as well as SPRINT-2 [18],
RESPOND-2 [21] and PROVIDE [22] for BOC), and take
into account the recently updated American Association for
the Study of Liver Diseases (AASLD) Practice Guidelines
[3] as well as the labels approved by the US Food and
Drug Administration, the European Medicinal Agency, and
Swissmedic. Current European Association for the Study
of the Liver (EASL) Clinical Practice Guidelines [2] are
expected to be updated shortly. In addition, different na-
tional guidelines are in preparation. Therefore, as recom-
mendations are emerging and as real-life data and practical
experience on the use of TPV and BOC are still limited, it
is strongly recommended to initiate and pursue triple ther-
apy comprising TPV or BOC only in close collaboration
with an expert centre.
Practical use of telaprevir and
boceprevir
TPV is available in the form of 375-mg film-coated tablets
and has to be taken at a dose of 750 mg every 8 hours
(i.e., two tablets every 8 hours), with a meal or a snack
containing ~20 g of fat to increase bioavailability. BOC is
available in the form of 200-mg capsules and has to be
taken at a dose of 800 mg every 8 hours (i.e., 4 capsules
every 8 hours), with a meal or a snack. Dosing every 8 ±
1 hour rather than 3 times per day is important to main-
tain inhibitory drug serum concentrations and to avoid an-
tiviral resistance development. TPV and BOC should never
be used alone, and doses should never be reduced. When
used alone, these drugs will not be effective and will cause
emergence of HCV strains with resistance to antiviral ther-
apy that could be difficult to treat subsequently. RBV can
be taken with the first dose of TPV or BOC in the morning
and with the last dose of TPV or BOC in the evening.
TPV and BOC are only approved for use in patients with
HCV genotype 1 infection. The development of antiviral
resistance is more frequent in subtype 1a than 1b but this
should not influence therapeutic decision making.
Table 1: Definition of virological response patterns.
Rapid virological response (RVR) Undetectable1 HCV RNA at week 4
Extended RVR (eRVR) Undetectable HCV RNA at weeks 4 and 122
RVR8 Undetectable HCV RNA at week 83
Early virological response (EVR) >2 log drop of HCV RNA at week 12
Complete EVR (cEVR)4 Undetectable HCV RNA at week 12
Partial EVR (pEVR) >2 log drop but still detectable HCV RNA at week 12
Delayed virological response (DVR)5 >2 log drop but still detectable HCV RNA at week 12, undetectable HCV RNA at week 24
Partial response (PR) >2 log drop of HCV RNA at week 12 but detectable at weeks 12 and 24
Null response (NR) <2 log drop of HCV RNA at week 12
Breakthrough (BT) Reappearance of HCV RNA at any time during treatment
Relapse HCV RNA undetectable at end of treatment but detectable within 24 wks of follow-up
Sustained virological response (SVR) Undetectable HCV RNA 24 weeks after the end of treatment
1 The term “undetectable” in this paper refers to HCV RNA below the limited of detection (as opposed to the limit of quantitation) of a sensitive real-time PCR assay.
2 Relates to triple therapy comprising telaprevir.
3 Relates to triple therapy comprising boceprevir, including a 4-week lead-in phase of pegylated interferon-α and ribavirin.
4 Designated as early virological response in the recent EASL Clinical Practice Guidelines (ref. 2).
5 Formerly designated as slow virological response.
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Both TPV and BOC have a strong potential for drug-drug
interactions, as they affect the metabolism of other drugs
metabolised through cytochrome P450 3A4 (CYP3A4) and
other pathways [24]. See package inserts, continuously up-
dated online databases (e.g., http://www.hep-druginterac-
tions.org, Epocrates, Medscape) and Leise et al. [25] for
known drug-drug interactions and contraindicated drugs.
Commonly used drugs that are contraindicated in combina-
tion with TPV or BOC include, among others, atorvastatin,
lovastatin, simvastatin, sildenafil, alfuzosin, carbamazepin,
phenytoin, oral midazolam, and St. John’s wort. Among
the drugs commonly used to manage adverse effects of
therapy, paracetamol and metoclopramide (but not dom-
peridone) are allowed. TPV and BOC may decrease
citalopram levels and efficacy.
Main adverse effects of TPV include anemia, nausea and
diarrhea, skin rashes and pruritus as well as anorectal dis-
orders. Rash should be managed in collaboration with an
experienced dermatologist and should follow recommend-
ations that have recently been summarised [26]. TPV has
to be discontinued if rash progresses and becomes severe.
Rare cases of DRESS (drug-related eosinophilia with sys-
temic symptoms) and Stevens Johnson syndrome/toxic epi-
dermal necrolysis have been observed. If either one is sus-
pected, all drugs have to be stopped immediately, followed
by emergency dermatological consultation.
Main adverse effects of BOC include anemia, with a sig-
nificant number of patients requiring concomitant eryth-
ropoietin treatment in phase II and III clinical trials, as well
as dysgeusia.
Anemia can develop rapidly and become very pronounced
with both TPV and BOC, especially in patients with cir-
rhosis. Therefore, close monitoring is recommended.
Anemia should be managed by timely RBV dose reduction
and, if needed, blood transfusions and/or erythropoetin.
Figure 1
Telaprevir-based triple therapy. (A) Treatment-naïve patients with
CHC genotype 1 and treatment-experienced patients with previous
relapse. (B) Treatment-experienced patients with CHC genotype 1
and previous partial or null response. eRVR, extended rapid
virological response (see table 1 for definitions of virological
response patterns); P, pegylated interferon-α; R, ribavirin; T,
telaprevir; wks, weeks.
Data on the safety and efficacy of TPV and BOC in patients
with HIV coinfection are emerging. TPV and BOC should
be used only in close collaboration with an expert in these
patients.
There is no data in liver transplant recipients, hemodialysis
patients and children, and the use of TPV and BOC in these
situations is currently proscribed.
In registration trials, TPV was used with PEG-IFN-α2a 180
µg per week plus RBV 1000–1200 mg per day and BOC
was used with PEG-IFN-α2b 1.5 µg/kg per week plus RBV
600–1400 mg per day. However, both forms of PEG-IFN-α
may be used with RBV and either TPV or BOC.
PEG-IFN-α is contraindicated in decompensated cirrhosis.
Strict contraception must be followed during and for 6
months after the end of triple therapy because of the poten-
tial teratogenicity of RBV.
Who should be treated with triple
therapy comprising TPV or BOC?
Triple therapy will represent a new standard for most
treatment-naïve patients with CHC genotype 1 as well as
treatment-experienced patients with a relapse or partial re-
sponse to previous therapy with PEG-IFN-α and RBV
(table 2).
Treatment of CHC is expected to change significantly with-
in the next few years, with the arrival of better tolerated and
Figure 2
Boceprevir-based triple therapy. (A) Treatment-naïve patients with
CHC of genotype 1 without cirrhosis. (B) Treatment-experienced
patients with CHC genotype 1 and previous relapse or partial
response without cirrhosis. (C) All cirrhotic patients and prior null
responders. B, boceprevir; BPR = B + P + R; P, pegylated
interferon-α; R, ribavirin; RVR8, rapid virological response at week
8 (see table 1 for definitions of virological response patterns); wks,
weeks.
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even more efficacious new drugs as well as the advent of
IFN-free/sparing regimens [27–30]. These developments
shall significantly improve the outlook for our patients.
Therefore, deferring treatment may be considered in pa-
tients who’s treatment can be safely postponed.
Treatment-naïve patients with favourable baseline predict-
ors (HCV RNA <4 x 105 IU/ml, absence of advanced
fibrosis or cirrhosis) who achieve a rapid virological re-
sponse (RVR; see table 1) have excellent chances to
achieve SVR with 24 weeks of therapy with PEG-IFN-
α and RBV alone [31]. Therefore, a 4-week lead-in with
PEG-IFN-α and RBV may be considered in patients with
the above-mentioned favourable baseline predictors and
treatment continued without adding TPV or BOC for a total
of 24 weeks in those who achieve RVR.
Lead-in with PEG-IFN-α and RBV may also be considered
if there are doubts concerning the tolerance or adherence to
PEG-IFN-α and RBV backbone therapy.
There is currently only limited data on the use of BOC
in patients with previous null response. In general, retreat-
ment of previous null responders has to be considered care-
fully, as SVR rates remain limited, especially in patients
with cirrhosis. Inclusion of such patients into clinical trials
involving quadruple therapy or IFN-sparing regimens may
be considered. Lead-in with PEG-IFN-α and RBV may be
considered in previous null responders, especially in cir-
rhotics, with the addition of TPV or BOC only in case
of ≥1 log decline of HCV RNA at week 4. Subanalysis
of the REALIZE trial revealed that 54% of the patients
with ≥1 log decline after 4 weeks of lead-in with PEG-IFN-
α and RBV achieved SVR with triple therapy comprising
TPV, compared to only 15% of those with a decline of
HCV RNA <1 log [32].
Careful monitoring and stopping rules, as detailed below,
shall reduce the risk of selecting HCV strains resistant to
antiviral therapy. While long-term consequences of the se-
lection of such strains are presently unknown, antiviral res-
istance is likely to affect future treatment options [15, 16].
Specific treatment algorithms
Telaprevir-based triple therapy
• Treatment-naïve patients and previous relapsers with
CHC genotype 1 (fig. 1A)
Non-cirrhotic patients who achieve eRVR
12 weeks TPV + PEG-IFN-α + RBV
+ 12 weeks PEG-IFN-α + RBV
Non-cirrhotic patients who do not achieve eRVR and all
cirrhotic patients
12 weeks TPV + PEG-IFN-α + RBV
+ 36 weeks PEG-IFN-α + RBV
• Previous partial and null responders with CHC geno-
type 1 (fig. 1B)
12 weeks TPV + PEG-IFN-α + RBV
+ 36 weeks PEG-IFN-α + RBV
Lead-in with PEG-IFN-α and RBV may be considered in
previous null responders, especially in cirrhotics, with the
addition of TPV only in case of ≥1 log decline of HCV
RNA at week 4.
Stopping rules:
– Stop all therapy if HCV RNA >1000 IU/ml at either
week 4 or 12 of triple therapy.
– Stop all therapy if HCV RNA detectable at wk 24.
– Stop all therapy if previously negative HCV RNA
becomes confirmed positive again under treatment.
Table 2: Who should be treated with triple therapy comprising telaprevir (TPV) or boceprevir (BOC)?
• Treatment-naïve patients with CHC genotype 1
→ Triple therapy new standard for most patients.
→ Consider PEG-IFN-α and RBV lead-in
• in patients with favorable baseline predictors (HCV RNA <4 x 105 IU/ml, lack of advanced fibrosis or cirrhosis);
• in case of doubt concerning adherence to PEG-IFN-α and RBV backbone.
• CHC genotype 1 relapsers or partial responders to previous treatment with PEG-IFN-α and RBV
→ Retreat with triple therapy.
→ Consider PEG-IFN-α and RBV lead-in in case of doubt concerning adherence to PEG-IFN-α and RBV backbone.
• CHC genotype 1 null responders to previous treatment with PEG-IFN-α and RBV
→ Carefully consider retreatment with triple therapy vs. await quadruple therapy or IFN-sparing regimens.
→ Consider PEG-IFN-α and RBV lead-in.
• Patients with genotypes other than 1
→ PEG-IFN-α and RBV.
CHC, chronic hepatitis C; PEG-IFN-α, pegylated interferon-α; RBV, ribavirin.
Table 3: Key points.
• Consider the natural history of hepatitis C and factors affecting disease progression.
• Considerate treatment indication crucial (Treat the disease, not the infection!).
• Triple therapy comprising TPV or BOC increases SVR rates to ~70%, with shortened treatment duration in ~½.
• Advances will come at the expense of new adverse effects and increased cost.
• Antiviral therapy will become more complex (patient education, adherence, treatment milestones, adverse effect management, laboratory infrastructure and turn-
around time, antiviral resistance).
• Limited or no data in patients with high unmet need (especially those with HIV coinfection and recurrent hepatitis C after liver transplantation).
• Available resources will be stretched.
• Liaise with an expert center.
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Boceprevir-based triple therapy
• Treatment-naïve patients with CHC genotype 1 (fig.
2A and 2C)
Non-cirrhotic patients who achieve RVR8
4 weeks PEG-IFN-α + RBV lead-in
+ 24 weeks BOC + PEG-IFN-α + RBV
Non-cirrhotic patients who do not achieve RVR8
4 weeks PEG-IFN-α + RBV lead-in
+ 24 weeks BOC + PEG-IFN-α + RBV
+ 20 weeks PEG-IFN-α + RBV
Cirrhotic patients
4 weeks PEG-IFN-α + RBV lead-in
+ 44 weeks BOC + PEG-IFN-α + RBV
• Previous relapsers or partial responders with CHC
genotype 1* (fig. 2B and 2C)
Non-cirrhotic patients who achieve RVR8
4 weeks PEG-IFN-α + RBV lead-in
+ 32 weeks BOC + PEG-IFN-α + RBV
Non-cirrhotic patients who do not achieve RVR8
4 weeks PEG-IFN-α + RBV lead-in
+ 32 weeks BOC + PEG-IFN-α + RBV
+ 12 weeks PEG-IFN-α + RBV*
Cirrhotic patients
4 weeks PEG-IFN-α + RBV lead-in
+ 44 weeks BOC + PEG-IFN-α + RBV
*For patients with prior null response, 4 weeks of lead-in
with PEG-IFN-α + RBV, followed by 44 weeks of triple
therapy with BOC + PEG-IFN-α + RBV is recommended.
Stopping rules:
– Consider stopping therapy in patients with cirrhosis and
<1 log drop of HCV RNA after lead-in (chances of
achieving SVR being 13–25% only [33]).
– Stop all therapy if HCV RNA ≥100 IU/ml at week 12.
– Stop all therapy if HCV RNA detectable at week 24.
– Stop all therapy if previously negative HCV RNA
becomes confirmed positive again under treatment.
Conclusions
Key points are summarised in table 3.
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Figures (large format)
Figure 1
Telaprevir-based triple therapy. (A) Treatment-naïve patients with CHC genotype 1 and treatment-experienced patients with previous relapse.
(B) Treatment-experienced patients with CHC genotype 1 and previous partial or null response. eRVR, extended rapid virological response (see
table 1 for definitions of virological response patterns); P, pegylated interferon-α; R, ribavirin; T, telaprevir; wks, weeks.
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Figure 2
Boceprevir-based triple therapy. (A) Treatment-naïve patients with CHC of genotype 1 without cirrhosis. (B) Treatment-experienced patients with
CHC genotype 1 and previous relapse or partial response without cirrhosis. (C) All cirrhotic patients and prior null responders. B, boceprevir;
BPR = B + P + R; P, pegylated interferon-α; R, ribavirin; RVR8, rapid virological response at week 8 (see table 1 for definitions of virological
response patterns); wks, weeks.
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